Jallapally, Anvesh published the artcile2-Butyl-4-chloroimidazole based substituted piperazine-thiosemicarbazone hybrids as potent inhibitors of Mycobacterium tuberculosis, Product Details of C13H18N2, the publication is Bioorganic & Medicinal Chemistry Letters (2014), 24(23), 5520-5524, database is CAplus and MEDLINE.
A series of 2-butyl-4-chloroimidazole based substituted piperazine-thiosemicarbazone hybrids was designed by combining three different pharmacophoric fragments in single mol. architecture. 2-Butyl-4-chloro-1-((3-(4-substituted)piperazin-1-yl)propyl)-1H-imidazole-5-carbaldehydes were prepared by reacting carboxaldehydes with N-alkylpiperazines and were subsequently condensed with thiosemicarbazide to give the desired compounds in very good yields. Among all sixteen compounds screened for in vitro antimycobacterial activity against Mycobacterium tuberculosis H37Rv (MTB), two compounds (E)-2-((2-butyl-4-chloro-1-(3-(4-(o-tolyl)piperazin-1-yl)propyl)-1H-imidazol-5-yl)methylene)hydrazinecarbothioamide and (E)-2-((2-butyl-4-chloro-1-(3-(4-(2-methoxyphenyl)piperazin-1-yl)propyl)-1H-imidazol-5-yl)methylene)hydrazinecarbothioamide were found to be the most potent antitubercular agents (MIC: 3.13 μg/mL) with low toxicity profile.
Bioorganic & Medicinal Chemistry Letters published new progress about 87179-40-6. 87179-40-6 belongs to piperazines, auxiliary class Benzenes, name is (E)-1-Cinnamylpiperazine, and the molecular formula is C13H18N2, Product Details of C13H18N2.
Referemce:
https://en.wikipedia.org/wiki/Piperazine,
Piperazines – an overview | ScienceDirect Topics